Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. — ME/CFS Atlas
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity.
Proal, Amy, Marshall, Trevor · Frontiers in pediatrics · 2018 · DOI
Quick Summary
This review explores the idea that ME/CFS may be caused by persistent infections (like Epstein-Barr virus) that disrupt the body's microbial communities and normal cell functions. These infections can interfere with how cells work, how genes are expressed, and how the immune system responds, potentially leading to the chronic symptoms patients experience. The authors suggest that treating ME/CFS might involve helping the immune system fight these persistent infections.
Why It Matters
This synthesis connects scattered microbiome research to ME/CFS pathophysiology, offering a unifying hypothesis that explains why different patients may have different triggers and symptom patterns. Understanding these mechanisms could guide development of targeted immune-supportive treatments rather than one-size-fits-all approaches.
Observed Findings
Gut microbiome dysbiosis has been identified in ME/CFS patients
Intracellular pathogens including EBV have been repeatedly associated with ME/CFS
Antibodies and clonal T cells identified in ME/CFS patients suggest prior or ongoing immune activation to persistent pathogens
Pathogenic organisms can directly interfere with human transcription, translation, and DNA repair processes
Multiple unrelated pathogens share similar mechanisms for disabling host immunity and metabolism
Inferred Conclusions
ME/CFS may result from persistent pathogen-driven microbiome dysbiosis rather than a single infectious agent
Symptom heterogeneity in ME/CFS may reflect differences in patients' unique infectious and environmental histories
Treatments supporting immune function to combat persistent infections may reverse ME/CFS pathology
Pathogenic mechanisms including molecular mimicry and direct cellular interference contribute to metabolic and immunological dysfunction
Remaining Questions
Which specific pathogen combinations or dysbiosis patterns are most common in ME/CFS, and do they correlate with symptom severity?
What This Study Does Not Prove
This review does not provide original experimental evidence that persistent pathogens directly cause ME/CFS symptoms, nor does it establish causation versus correlation. The proposed mechanisms (molecular mimicry, metabolic interference, mitochondrial dysfunction) are discussed as plausible pathways but are not definitively demonstrated in ME/CFS populations in this article.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
How can the proposed mechanisms (molecular mimicry, metabolic interference) be experimentally validated in ME/CFS patient samples?
What immune-supportive treatments would effectively reverse pathogen-driven dysbiosis in ME/CFS populations?
Which patients are most likely to benefit from pathogen-targeting versus general immune-supportive approaches, and how can this be determined clinically?